1Susan V, McLennan, Elizabeth Fisher, et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: Possible role in diabetic nephropathy. Kidney Int, 2000,58 (suppl. 77 ): S81-87.
2Crawford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis, 1995,14:24-245.
3Sukhova GK, Schonbeck V, Rabkin E, et al. Evidence for increased collagenolysis by interstitial. collagenases-1 and 3 in vulnerable areas of human atheromatous plaques. Circulation, 1999,99: 2503-2509.
4Wysoki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol, 1993,101: 64-68.
5Benbow U, Brinckerhoff C. The AP-1 site and MMP gene regulation: what is all the fuss about. Matrix Biol, 1997,15: 519-526.
6Schutte J, Viallet J, Nau M, et al. JunB inhibits and c-fos stimulates the transforming and trans-activaing activities of c-jun. Cell, 1989,59:987-999.
7Mauviel A, Chung K, Agarwal A, et al. Cell-specific induction of distinct oncogenes-of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-beta in fibroblasts and keratinocytes. J Biol Chem, 1996,271:10917-10923.
8Haas TL, Davis SJ, Madri JA. Three dimensional type 1 collagen lattices induce coordinate expression matrix metalloproteinases MT-1 MMP and MMP-2in microvascular endothelial cell. J Biol Chem, 1998,273: 3604-3610.
9Lohi J, Lehti K, Westermarck J, et al. Regulation of membrane-type metalliproteinase expre ssion by growth factors and phorbol 12-myristate 13 acetate. Eur J Biochem, 1996,239: 239-249.
10Mo W, Brecklin C, Garder SL, et al. Changes in collagenase and TGF-β precede structural alterations in a model of chronic renal fibrosis. Kidney Int,1999,56:145-153.
1Raij L, Azar S, Keane W. Mesangial immune injury hypertension, and progressive glomerular damage in Dahl rats [ J ]. Kidney Int, 1984,26 : 137.
2Tanaka R, Sugihara K. Internephron heterogeneity of growth factors and sclerosis - modulation of platelet - derived growth factor by an- giotensin [ J ]. Kidney Int, 1995,47 : 131.
3Song Y, Li C, Cai L. Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediat- ed extracellular matrix accumulation [ J ]. Expert Molec Pathol, 2004, 76(1) : 66-75.
4Zafarullah M, Li WQ, Sylvester J, et al. Molecular mechanisms of N-acetylcysteine actions [ J ]. Cell Mol Life Sci,2003,60 ( 1 ) 6-20.
8Yamagishi S, Fukami K, Ueda S, et al. Molecularmechanisms of di- abetic nephropathy and its therapeuticintervention [ J ]. Curr Drug Targets, 2007, 8 (8) : 86 -95, 952.
9Schnaper HW. Balance between matrixs mathesis and degrada - tion : a determiant of glomeruioeclerosis [J] . Pediatr. pediatr Nephrol 1995, 9 (1): 104-111.
10Toblli je, ferrini mg, cao g, et al. Anti - fibrotic effects of pioglita- zone on the kidney in a rat model of type 2 diabetes mellitus [ J ] Nephrol Dial Transplant, 2009, 24 (8) : 2 384 -2 391.
